Literature DB >> 12466353

Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone.

Corrine K Welt1, Ann E Taylor, Kathryn A Martin, Janet E Hall.   

Abstract

Inhibin B is a product of the granulosa cells of growing preantral and antral follicles. Despite the large ovarian volume and increased follicle number typically detected in women with polycystic ovary syndrome (PCOS), previous studies demonstrate that inhibin B is not elevated as would be expected in PCOS, but is inversely correlated with body mass index (BMI). We therefore hypothesized that inhibin B levels in women with PCOS are regulated by a factor related to BMI. Thus, LH, sex steroids, and metabolic parameters were measured in 50 anovulatory PCOS subjects in pools constituted from equal aliquots of serum drawn every 10 min for 4 h and were correlated with inhibin B. Based on the results of these correlative studies, inhibin B regulation by human chorionic gonadotropin (hCG) and insulin was tested directly. In PCOS subjects, inhibin B correlated inversely with BMI (r = -0.413; P < 0.004) and fasting insulin (r = -0.409; P < 0.004). Inhibin B also correlated directly with pool LH (r = 0.419; P < 0.003), LH pulse amplitude (r = 0.512; P < 0.0001), and SHBG (r = 0.429; P < 0.003). The relationships demonstrated for inhibin B were not demonstrated for inhibin A, nor were they evident in normal subjects. To determine whether the correlations represent regulation of inhibin B, i.e. stimulation of inhibin B by LH or suppression by insulin, two interventional studies were performed. In the first study hCG (5000 U) was administered to PCOS subjects (n = 15) to mimic the effects of LH. Inhibin B was not increased, but was significantly reduced 24 h after hCG administration (223.8 +/- 21.3 vs. 152.4 +/- 15.9 pg/ml; P < 0.0005). In the second study, diazoxide (100 mg every 8 h) was administered for 3 d to PCOS subjects (n = 9). Inhibin B increased (85.4 +/- 12.4 to 136.6 +/- 18.8 pg/ml; P < 0.05) in association with a decrease in the insulin area under the curve (104 +/- 29 to 83 +/- 22 nmol/liter.min; P < 0.05) induced by diazoxide. In PCOS subjects, inhibin B demonstrated significant relationships with BMI and factors related to BMI, including LH, insulin, and SHBG. Although LH was associated with inhibin B, hCG administration suppressed inhibin B secretion after 24 h, whereas short-term insulin suppression increased inhibin B. These findings suggest that both increased LH and insulin may account for the relative suppression of inhibin B in patients with PCOS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466353     DOI: 10.1210/jc.2002-020546

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Luteal-phase inhibin A and follicular-phase inhibin B levels are not characteristic of patients with an elevated LH-to-FSH ratio.

Authors:  Erik E Hauzman; Péter Fancsovits; Akos Murber; Thomas Rabe; Thomas Strowitzki; Zoltán Papp; János Urbancsek
Journal:  J Assist Reprod Genet       Date:  2006-03       Impact factor: 3.412

2.  Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene Expression in the Arcuate Nucleus of a PCOS Mouse Model.

Authors:  Lourdes A Esparza; Danielle Schafer; Brian S Ho; Varykina G Thackray; Alexander S Kauffman
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

Review 3.  Diagnostic criteria for polycystic ovarian syndrome.

Authors:  F J Broekmans; B C J M Fauser
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 4.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

5.  Characterization of functionally typical and atypical types of polycystic ovary syndrome.

Authors:  Jennifer Hirshfeld-Cytron; Randall B Barnes; David A Ehrmann; Anthony Caruso; Monica M Mortensen; Robert L Rosenfield
Journal:  J Clin Endocrinol Metab       Date:  2009-02-24       Impact factor: 5.958

6.  Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome.

Authors:  Rana F Shayya; Marcus A Rosencrantz; Sandy S Chuan; Heidi Cook-Andersen; William E Roudebush; H Irene Su; Shunichi Shimasaki; R Jeffrey Chang
Journal:  Fertil Steril       Date:  2013-11-01       Impact factor: 7.329

7.  Inhibin secretion in women with the polycystic ovary syndrome before and after treatment with progesterone.

Authors:  Konstantinos Dafopoulos; Christos Venetis; Christina I Messini; Spyros Pournaras; George Anifandis; Antonios Garas; Ioannis E Messinis
Journal:  Reprod Biol Endocrinol       Date:  2011-04-29       Impact factor: 5.211

8.  The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome.

Authors:  Basil O Saleh; Wasan F Ibraheem; Nada S Ameen
Journal:  Saudi Med J       Date:  2015-05       Impact factor: 1.484

9.  Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin-Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results.

Authors:  Aylin Yetim; Çağcıl Yetim; Firdevs Baş; Oğuz Bülent Erol; Gülnaz Çığ; Ahmet Uçar; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.